Horizon Discovery has introduced Edit-R CRISPRa arrayed CRISPR RNA (crRNA) libraries, the latest addition to its CRISPR activation (CRISPRa) reagent platform from the recently acquired Dharmacon business. The new libraries offer a powerful tool for drug discovery, pathway analysis and disease progression studies.
Unlike lentiviral pooled screens, Edit-R synthetic crRNA arrayed libraries enable one-gene-per-well investigation, using high-content assays to answer more in-depth biological questions. A CRISPRa-based system for overexpression studies also overcomes many of the shortcomings of early generations of DNA plasmid-encoded gene expression tools. By triggering the endogenous gene’s expression, the gene is transcribed in its native form, so researchers can be assured of highly relevant results in their cell system.
The Edit-R CRISPRa portfolio includes catalogue libraries for popular human and mouse gene families, such as ubiquitin enzymes, transcription factors, and kinases, in addition to drug-targeted genes and the whole human genome. Bespoke collections are also available to support researchers working with a specialised gene target list.
More information on Horizon’s CRISPRa reagents and screening services is available online.
www.horizondiscovery.com/research-services/functional-genomicscreening/crispr-screening